3rd Annual Pharmacovigilance & Drug Safety Summit

Staying up to date with Regulation, Signal and Risk Management during the Covid-19 Pandemic

25 — 26 March, 2021 Virtual Summit

The event has already occured.

Key facts

Date: 25 — 26 March, 2021

Place: Virtual Summit

Conference Overview

As Pharmacovigilance systems are changing significantly around the world, it is very important companies remain updated at all times. Adding to this the rising demand for drugs, the amplified need for novel therapeutics development via extensive clinical trials and the world population growth made drug manufacturers to start to pay more attention to Pharmacovigilance field as public anxiety about safety increases.

Furthermore the growth of artificial intelligence and combination products, signal management is ever more important. It is important to meet the right people and understand the regulatory changes with IDMP, combo products as well as being prepared for inspections and audits.

On this B2B event participants will have the chance to learn more about this challenging era and the latest developments in Pharmacovigilance and Drug Safety with the main key players in this field.

This event will be focusing on trends on Regulatory Challenges, Signal Detection, Data Management, Risk management, Audit & Inspection and New Technology applied to Pharmacovigilance procedures.

We invite you to discuss and debate these challenges in a dialogue amongst top professionals in Pharmacovigilance.

Key topics

  • Impacts of PV on Covid-19
  • Improving Signal surveillance
  • Artificial Intelligence in Signal Detection
  • Combination products – Regulation, trials, and risk management
  • The role of data mining in Pharmacovigilance and its benefits
  • IDMP standards and strategy
  • Developing a pharmacovigilance risk management plan with a risk minimization action plan (RiskMAP) for high risk products
  • Understanding how Artificial Intelligence is transforming pharmacovigilance
  • Evaluation of quality and manufacturing in production
  • Audits and Inspections
  • Strengthening Pharmacovigilance quality management system
  • Impact of AI in Pharmacovigilance
  • Upcoming regulatory changes
  • Signal management
  • Application of data analytics in Pharmacovigilance processes to increase speed of signal detection

Who should attend

CEOs / Presidents / MDs, CCOs/CMOs/CDOs, Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, and Managers specialising in:

  • Assurance & Compliance
  • Quality Assurance
  • Quality Control
  • Data Analysis
  • Pharmacovigilance
  • Pharmacology
  • Pharmacoepidemiology
  • Epidemiology
  • Medical Information
  • Health Outcomes
  • PSUR/PBRER
  • Clinical Data Management
  • MedDRA
  • PV Agreements
  • PASS/PAES
  • PSMF
  • CAPA
  • QPPV
  • Medical Affairs
  • Adverse Drug Reactions
  • Drug/Product Safety
  • Drug Development
  • RMPs
  • GPvP
  • ICH-GCP
  • Clinical Pharmacology
  • Clinical Safety
  • Clinical Trials
  • Clinical Trial Management
  • Clinical Development
  • Clinical Research
  • Risk Management
  • Research & Development
  • Patient Safety
  • Signal Detection
  • Signal Management
  • Safety Surveillance
  • Safety Databases
  • Safety Evaluation
  • Outcome Research
  • Regulatory Affairs and Compliance
  • Data management and data mining
  • Benefit-Risk Assessment
  • Regulatory Submissions
  • PV Governance
  • Safety Management
  • Pharmacovigilance Operations
  • PV Inspection and Audit Readiness
  • Patient Support Programs
  • Medical Safety
  • Medical Product Safety Assessment
  • Phase IV/Postmarketing Safety

Event Speakers

Dr. JUHAERI JUHAERI

Vice President and Head, Epidemiology and Benefit-Risk

Sanofi

DR. DIMITRIS ZAMPATIS

Scientific Director, Safety Strategy Lead

Merck Healthcare

MICHAEL GLASER

Safety Innovation Technology Director

GlaxoSmithKline

CLAUDIA NOLTE

Director, Global Pharmacovigilance & Regulatory Quality Assurance (PVRQA)

CSL Behring

DR. SUMIT MUNJAL

Vice President, Global Patient Safety Evaluation

Takeda Pharmaceuticals

STEPHANIE TCHERNY-LESSONOT

Head of Benefit-risk Evaluation, Epidemiology and Benefit-risk Evaluation

Sanofi

ANDREA OLIVA

Head of Pharmacovigilance

Viatris

ISRAEL GUTIERREZ

VP Pharmacovigilance and Drug Safety

Geron

ROBERT WEBER

Product Management Director

Oracle

DENNIS VAN LIEW

Associate Partner

Red Nucleus R&D

MICHAEL VON FORSTNER

Senior Director Patient Safety - Benefit Risk Management

PRA Health Sciences

RAJ BHOGAL

Senior Director, R&D Audits & Inspections

Jazz Pharmaceuticals

MARIE AAVANG GEIST

Head of Clinical Safety

Orphazyme

DR. ANUPAM AGARWAL

Vice President, Global Head of Drug Safety and Pharmacovigilance

Zogenix

Dr. MASSOUD TOUSSI

Global Offering Lead, Pharmacoepidemiology and Safety, Real World Evidence & Analytics

IQVIA

Companies attending the conference

Pictures from previous events

Video from previous events

Subscribe to our newsletter

Receive exclusive offers & the latest news on our events and services.

GlobalBSG uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Quick contact

info@globalbsg.com

+420 210 022 063

Politickych Veznu 912/10, Nove Mesto. 11000 Prague 1, Czech Republic

© 2025 GlobalBSG. All rights reserved.